$SYBX

Synlogic (SYBX) details board, compensation and major holders in 2025 10-K/A

Synlogic, Inc. has filed an amendment to its 2025 Annual Report (10-K/A) to provide detailed information on its board of directors, executive and director compensation, corporate governance, and major shareholders. The filing reveals that the company's Board consists of four independent directors, and as of March 31, 2026, Synlogic had only one full-time employee focused on strategic transactions. Key financial figures include Principal Executive and Financial Officer Mary Beth Dooley's 2025 compensation of $335,500 and audit fees paid to KPMG LLP totaling $365,000 for the same year.

Original reporting
Published May 1, 2026, 4:09 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 1, 2026, 4:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$SYBX
Neutral
medium confidence
Mentioned
$SYBX
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$SYBXNeutralLow
01

Why it matters

The filing is informational, with no immediate operational or financial changes disclosed.

02

Market read

The news has limited immediate trading impact but contributes to transparency and investor confidence.

03

What to watch

The low relevance score suggests limited impact; however, if Synlogic announces operational changes in the future, this could alter the outlook.

Timing: low

Background

Synlogic's 10-K/A filing updates shareholders on governance and compensation, reflecting ongoing corporate transparency efforts.

Company-level read

Ticker impact

$SYBXNeutralMedium confidence
Context

The news pertains to Synlogic's 2025 annual report amendment, highlighting corporate governance and compensation details.

Expected impact

negligible; no significant short-term price movement expected.

Evidence & confidence

The information is largely factual and already priced in; no new strategic insights or catalysts are present.

Market effects

Limited; the news does not indicate operational changes or strategic shifts in the biotech sector.

Minimal; the filing is specific to Synlogic and does not affect regional markets.

Negligible; the content is company-specific with no broader global implications.

Counterpoint

Some investors may interpret increased transparency as a positive signal, potentially supporting stock stability.

Key entities

  • Synlogic, Inc.

    A biotech company focused on developing microbiome-based therapeutics.

  • Mary Beth Dooley

    Principal Executive and Financial Officer of Synlogic.

  • KPMG LLP

    Auditor responsible for 2025 financial statement audit.

Related articles

$SYBXMedAI 8/10

Synlogic and Caldera Therapeutics Announce Merger and $278 Million Private Placement

The merger will create a publicly traded company focused on advancing Caldera's lead inflammatory bowel disease therapy, with financing expected to fund operations into 2029. Key Investor Takeaways Synlogic (USOTC:SYBX) agreed to merge with privately held Caldera Therapeutics in an all-stock transaction to create a new public company. A concurrent upsized private placement is expected to raise approximately $278 million to support development of CLD-423 through Phase 2 clinical trials.

$SYBXMedAI 8/10

Synlogic, Caldera Therapeutics Announce All

Synlogic and Caldera Therapeutics agreed to merge in an all-stock deal creating a Nasdaq-listed biotech under the Caldera name, targeting ticker CALD. Caldera secured $278 million in private placement funding plus existing cash to fund operations into 2029. Proceeds support Phase 2 trials of CLD-423 in ulcerative colitis and Crohn’s disease; Phase 1 data show good tolerability and >40-day half-life.

$SYBXMedAI 9/10

Synlogic To Merge With Caldera In All Stock Deal

Synlogic (SYBX) agreed to merge with Caldera Therapeutics (Caldera) in an all-stock deal. The combined company will be Caldera Therapeutics, a new holding company, and intends to list on Nasdaq under ticker CALD. A concurrent private placement is expected to raise about $278 million gross to fund Phase 2 CLD-423 and operations into 2029.

$BAHighAI 9/10

Boeing Wins $131.23B F-15 Eagle Crest Contract by U.S. DoW

Boeing secured a $131.23B contract for the F-15 Eagle Crest program, supporting U.S. Air Force and international customers. The deal covers production, upgrades, and maintenance, with work in St. Louis until 2037. Initial funds of $343,740 were obligated. Foreign Military Sales are included.